Elecsys® Immunoassay Breakthrough for Early Preeclampsia Detection

May 25, 2016

A team of researchers have come up with a ratio for two placental proteins that can be used to predict the onset of preeclampsia. The Elecsys® immunoassay sFlt-1:PlGF ratio, when coupled with other diagnostic and clinical information, allows physicians to provide more accurate diagnoses and prescribe patients with the necessary treatments.

1,273 pregnant women from 14 different countries with suspected preeclampsia participated ina study lead by Stefan Velohren, MD, PhD. Each participant underwent a blood test to determine the ratio of serum sFlt-1 to PlGF. Results showed that if the sFlt-1 to PlGF ratio was 38 or lower, patients were not likely to develop preeclampsia within one week. However, patients whose blood tests indicated higher ratio values showed an increased likelihood of developing preeclampsia or adverse fetal outcomes within the next four weeks.

Preeclampsia is a potentially life threatening syndrome characterized by high blood pressure and organ system damage that affects 2 – 5% of pregnancies around the world. Oftentimes, preeclampsia is diagnosed too late because of its variable clinical presentation and overlapping symptoms with other conditions. While treatments are available, delivery is the only real cure.

Preeclampsia has been linked with problems of the placenta. According to Dr. Verlohren, placental development is highly dependent on blood vessel formation. “In particular, soluble fms-like tyrosine kinase-1 (sFlt-1) (a molecule that inhibits blood vessel growth) is increased and placental growth factor (PlGF) (a molecule that encourages blood vessel growth) is decreased. This study has established that the ratio of these two molecules (sFlt-1:PlGF) can be used to predict whether preeclampsia will develop or not.” he adds.

Dr. Verlohren emphasized that the Elecsys® immunoassay sFlt-1:PlGF ratio should not be used as a standalone test. Instead, he recommended that physicians use the ratio as an additional tool for decision making in cases of suspected preeclampsia.

AIV Inc. provides a wide range of fetal monitoring solutions to help ensure maternal and fetal safety. To browse through our available fetal monitoring transducers, accessories, replacement parts and repair services, visit http://aiv-inc.com/fetal-monitor-transducers.html today!

About the Author

Laura Collier

Laura Collier

Laura Collier has a Bachelor’s Degree in Communications and a Master’s Degree in Business Administration from the University of North Florida. She is the Marketing Manager at AIV, Inc.

AIV Catalog

Request Your Printed or Electronic Copy Today!
We Respect Your Privacy

Be Part of Our
Biomed Community

Healthcare technology management professionals are a vital link in hospital operations, and we proudly support the national, state, and local associations with ongoing support and resources.

Get Biomed Resources

Why buy from AIV

AIV strives to provide you cost effective options to service equipment. We offer flexible solutions to best suit your needs.